Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03404310 · ClinicalTrials.gov registry record · NA
Zinc Sulfate for Human Papillomavirus (HPV)
A NA study, sponsored by Corewell Health West.
- Terminated
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT03404310 is a NA study that was terminated before completion, run by Corewell Health West. The registered enrollment target is 21 participants.
The verdict
NCT03404310, a NA study, was terminated before completion, sponsored by Corewell Health West.
- TERMINATED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The Human Papillomavirus (HPV) is well established as the primary causative agent in both warts and cervical cancer. Although cervical high risk HPV (hrHPV) infections have a high rate of spontaneous resolution this takes time and the infection can cause cervical cells to progress to precancerous and cancerous lesions. Zinc has been shown to play a central role in immunity. This study is to determine if oral zinc sulfate can improve clearance rates of high risk HPV versus placebo.
Interventions
- DIETARY_SUPPLEMENT Zinc Sulfate
- OTHER Placebo (Gelatin Tablet)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-10-24 |
| Est. Completion | 2019-06-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03404310
The ClinicalTrials.gov registry entry for NCT03404310 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corewell Health West, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zinc Sulfate is the first listed.
NCT03404310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03404310 about?
NCT03404310 is a clinical study titled "Zinc Sulfate for Human Papillomavirus (HPV)". The Human Papillomavirus (HPV) is well established as the primary causative agent in both warts and cervical cancer. Although cervical high risk HPV (hrHPV) infections have a high rate of spontaneous resolution this takes time and the infection can cause cervical cells to progress to precancerous an...
What is the current status of trial NCT03404310?
This trial is currently terminated. It is a NA study. The enrollment target is 21 participants. The study started on 2017-10-24. Estimated completion is 2019-06-28.
What interventions are being tested in trial NCT03404310?
The interventions under investigation include: Zinc Sulfate (DIETARY_SUPPLEMENT), Placebo (Gelatin Tablet) (OTHER).
Who is sponsoring clinical trial NCT03404310?
This trial is sponsored by Corewell Health West, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.